GlassScriptPhysician profile
Madison Leigh Ricks
NPI 1770256752
$6,492.72
in general payments reported to CMS, 2019-2025
25 companies · $2,144 in 2025
The $2,144 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,684 · 2024: $2,665 · 2025: $2,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,353 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,352.74 |
| Education | $139.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $882.83 | 2023-2025 | |
| Janssen Biotech, INC. | $787.62 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $673.87 | 2023-2025 | Dupixent, Libtayo |
| Ucb, INC. | $651.01 | 2023-2025 | Bimzelx |
| Incyte Corporation | $511.52 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $470.59 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $327.34 | 2023-2025 | Aklief |
| Sun Pharmaceutical Industries INC. | $321.67 | 2023-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $297.06 | 2023-2025 | |
| Organon LLC | $220.85 | 2025 | Vtama |
| Leo Pharma INC. | $201.97 | 2025 | Adbry, Anzupgo, Spevigo |
| Dermavant Sciences, INC. | $184.21 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $181.27 | 2023 | |
| Genzyme Corporation | $163.78 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $163.69 | 2024-2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $105.74 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $76.46 | 2023 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $58.99 | 2023-2024 | Siliq, Targretin, Duobrii |
| Botanix Sb INC | $50.19 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.28 | 2023-2025 | Spevigo |
| Organogenesis INC. | $36.61 | 2025 | Cygnus Dual |
| Merck Sharp & Dohme LLC | $28.54 | 2024 | Keytruda |
| Journey Medical Corporation | $22.06 | 2025 | |
| Lnhc, INC | $18.18 | 2025 | Zelsuvmi |
| Strata Skin Sciences, INC. | $14.39 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Ricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.